EUVIMEDEUVIMED entdecken
Open Access

Catatonia treatments and risk of recurrence

Liliana Patarroyo-Rodriguez, Laura Duque, Vanessa K Pazdernick, Jesse R Burson, Balwinder Singh

Journal of Affective Disorders · 2026

DOI: 10.1016/j.jad.2026.121734 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Affective Disorders, 2026. Verfasst von Liliana Patarroyo-Rodriguez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, 55905, USA. Hauptthemen laut MEDLINE: Catatonia, Antipsychotic Agents, Electroconvulsive Therapy, Benzodiazepines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Catatonia is a recurrent neuropsychiatric syndrome affecting approximately 9% of psychiatric inpatients, yet the impact of acute treatment strategies on long-term recurrence risk remains poorly understood. This study examined how treatments administered during acute catatonic episodes influence recurrence risk. METHODS: We conducted a retrospective cohort study of 205 adults hospitalized with catatonia at a tertiary care center between 2001 and 2021. Catatonia diagnoses were confirmed by chart review using Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria. The primary outcome was time to a new catatonic episode, with patients censored at last follow-up if no recurrence was observed. Treatment exposure was ascertained from the Latest Catatonia Episode (LaCE) for non-recurrent patients and from the Nearest Antecedent Catatonia Episode (NACE) for those with recurrence. Cox proportional hazards models estimated adjusted hazard ratios for benzodiazepines, antipsychotics, electroconvulsive therapy, and mood stabilizers, controlling for age and. RESULTS: Overall, 31% of patients experienced recurrence over a median follow-up of 6.4 years. Benzodiazepines, used in 88% of patients, were consistently protective against recurrence (adjusted hazard ratio 0.50, 95% confidence interval 0.27-0.94, p = 0.03). Antipsychotics demonstrated a biphasic effect: lower hazard of recurrence within 60 days (adjusted hazard ratio 0.36, 95% confidence interval 0.13-1.00, p = 0.05) but associated with increased hazard thereafter (adjusted hazard ratio 2.14, 95% confidence interval 1.08-4.254, p = 0.08). CONCLUSIONS: Benzodiazepines use was associated with sustained protection against catatonia recurrence. The time-dependent antipsychotic effect warrants careful consideration in maintenance treatment planning. While our retrospective design limits causal inference, these findings emphasize the need for prospective studies to optimize maintenance strategies and prevent recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CatatoniaAntipsychotic AgentsElectroconvulsive TherapyBenzodiazepinesHumansFemaleRetrospective StudiesRecurrenceMaleAdultMiddle AgedProportional Hazards ModelsAntimanic AgentsAged

Stichwörter der Autor:innen

AntipsychoticsBenzodiazepinesCatatoniaECTRecurrence

Substanzen

Antipsychotic AgentsBenzodiazepinesAntimanic Agents

Autor:innen und Institutionen

  • Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, 55905, USA.
  • Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, 55905, USA.; Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA.
  • Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, 55905, USA.. Electronic address: singh.balwinder@mayo.edu.

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institutes of Health
  • Mayo Clinic

Zitieren

APA

Patarroyo-Rodriguez, L., Duque, L., Pazdernick, V. K., Burson, J. R., & Singh, B. (2026). Catatonia treatments and risk of recurrence. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2026.121734

Vancouver

Patarroyo-Rodriguez L, Duque L, Pazdernick VK, Burson JR, Singh B. Catatonia treatments and risk of recurrence. Journal of Affective Disorders. 2026. doi:10.1016/j.jad.2026.121734

BibTeX
@article{PatarroyoRodriguez2026,
  author = {Patarroyo-Rodriguez, Liliana and Duque, Laura and Pazdernick, Vanessa K and Burson, Jesse R and Singh, Balwinder},
  title = {Catatonia treatments and risk of recurrence},
  journal = {Journal of Affective Disorders},
  year = {2026},
  doi = {10.1016/j.jad.2026.121734}
}
Kostenlos starten →